Naftzger J. Christopher has filed 6 insider transactions across 1 company since July 2023.
Most recent transaction: a grant/award of 54300 shares of Arbutus Biopharma Corp ($ABUS) on February 14, 2025.
Activity breakdown: 0 open-market purchases and 1 sale.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 14, 2025 | Arbutus Biopharma Corp | $ABUS | Naftzger J. Christopher | General Counsel and CCO | A | Common Shares | 54300 | $0.00 | 140,544.0000 | 0 | 62.96% | 0.00% |
| Feb. 14, 2025 | Arbutus Biopharma Corp | $ABUS | Naftzger J. Christopher | General Counsel and CCO | A | Stock Option (Right to Buy) | 220300 | $0.00 | 220,300.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | Arbutus Biopharma Corp | $ABUS | Naftzger J. Christopher | General Counsel and CCO | S | Common Shares | 11333 | $3.28 | 86,244.0000 | 0 | 11.61% | 0.00% |
| Feb. 1, 2024 | Arbutus Biopharma Corp | $ABUS | Naftzger J. Christopher | General Counsel and CCO | A | Common Shares | 95100 | $0.00 | 95,100.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2024 | Arbutus Biopharma Corp | $ABUS | Naftzger J. Christopher | General Counsel and CCO | A | Stock Option (Right to Buy) | 380500 | $0.00 | 380,500.0000 | 0 | 9999.99% | 0.00% |
| July 10, 2023 | Arbutus Biopharma Corp | $ABUS | Naftzger J. Christopher | General Counsel and CCO | A | Stock Option (Right to Buy) | 500000 | $0.00 | 500,000.0000 | 0 | 9999.99% | 0.00% |